Inspire Pharmaceuticals Inc. announced unaudited financial results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported total revenue of $25,168,000, loss from operations of $7,932,000, net loss of $8,493,000 or $0.12 per basic and diluted share against total revenue of $19,952,000, loss from operations of $9,033,000, net loss of $9,619,000 or $0.17 per basic and diluted share a year ago. For the nine months, the company reported total revenue of $62,550,000, loss from operations of $35,460,000, net loss of $37,411,000 or $0.61 per basic and diluted share against total revenue of $51,639,000, loss from operations of $40,760,000, net loss of $41,894,000 or $0.74 per basic and diluted share a year ago.

Inspire Pharmaceuticals, Inc. expected to Report Fiscal Year 2009 Results on March 1, 2010. This event was calculated by Capital IQ (Created on November 5, 2009).

Inspire Pharmaceuticals Inc. announced patient enrollment is complete in three of its late-stage clinical trials. Inspire announced that TIGER-2, the company's second Phase 3 pivotal clinical trial (Trial 08-110) with denufosol tetrasodium inhalation solution for the treatment of cystic fibrosis (CF), has completed patient enrollment. TIGER-2 is a 48-week trial comparing 60 mg of denufosol to placebo, administered three-times daily by jet nebulizer in a targeted 450 CF patients. The company expects to have top-line results from TIGER-2 in the first quarter of 2011. Inspire also announced that patient enrollment is complete in its Phase 3 clinical trial (Trial 03-113) with PROLACRIA, the proposed U.S. tradename for diquafosol tetrasodium ophthalmic solution 2%, for the treatment of dry eye disease. This is a six-week trial comparing PROLACRIA to placebo, administered four-times daily as eye drops, in a targeted 450 dry eye patients. The trial is based on a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA). The Company expects to have top-line results from this trial in the first quarter of 2010. The AZASITE (azithromycin ophthalmic solution) 1% for blepharitis Phase 2 program is targeted to enroll approximately 600 patients in two trials. One trial (Trial 044-101) includes a two-week treatment period with a two-week follow-up period and the other trial (Trial 044-102) includes a four-week treatment period with a four-week follow-up period. Inspire announced that enrollment is complete in the four-week trial and enrollment in the two-week trial is progressing well with 250 out of a targeted 300 patients enrolled. The company expects to have enrollment completed in the two-week trial in the first quarter of 2010.